FDA Inspection 1251714 — Glaukos Corporation
The FDA completed an inspection of Glaukos Corporation on Aug 15, 2024 in San Clemente, CA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Aug 15, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- San Clemente, CA (United States)
Additional details
Postmarket Adverse Drug Experience (PADE)